Andrew R. Adams
Mairs & Power Growth Fund
Mairs & Power Growth Fund Medtronic PLC stake
total: 93
Mairs & Power Growth Fund MDT trades
- Total transactions:
- 13
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 7
- Held since:
- 2019 Q3
- Held for:
- 21 quarters
- Latest activity:
- 2024 Q4
According to 2026 Q1 report, Mairs & Power Growth Fund doesn't hold any Medtronic PLC (MDT) shares. To date, the estimated cost basis is nearly $104.49 for "buy" trades and estimated average "sell" price is $92.89. Mairs & Power Growth Fund first purchased MDT in 2019 Q3, initially acquiring about 1.73M shares. Since the initial investment in Medtronic PLC (MDT), Mairs & Power Growth Fund has made 12 more transactions.
When did Mairs & Power Growth Fund sell Medtronic PLC (MDT)?
Mairs & Power Growth Fund sold off the entire Medtronic PLC (MDT) position in 2024 Q4.
When did Mairs & Power Growth Fund buy Medtronic PLC (MDT)?
Mairs & Power Growth Fund first invested in Medtronic PLC (MDT) in 2019 Q3 at the reported quarter-end price of $108.62 per share.
What's the cost basis of Mairs & Power Growth Fund's MDT stake?
The estimated cost basis for Medtronic PLC (MDT) stake is around $104.49 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $104.49
- Weighted AVG sell price:
- $92.89
Mairs & Power Growth Fund's historical trades in Medtronic PLC
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.00%
|
0
|
$90.03
|
|
-100% (-981,000)
|
-1.55%
|
|
2024 Q3
|
1.55%
|
981,000
|
$90.03
|
$88,319,430
|
-44.26% (-779,000)
|
-1.26%
|
|
2023 Q3
|
3.06%
|
1,760,000
|
$78.36
|
$137,913,600
|
+8.37% (+136,000)
|
+0.24%
|
|
2022 Q3
|
3.10%
|
1,624,000
|
$80.75
|
$131,138,000
|
+9.14% (+136,000)
|
+0.26%
|
|
2022 Q2
|
2.99%
|
1,488,000
|
$89.75
|
$133,548,000
|
-1.65% (-25,000)
|
-0.04%
|
|
2022 Q1
|
3.09%
|
1,513,000
|
$110.95
|
$167,867,350
|
-6.02% (-97,000)
|
-0.18%
|
|
2021 Q3
|
3.69%
|
1,610,000
|
$125.35
|
$201,813,500
|
-1.53% (-25,000)
|
-0.06%
|
|
2021 Q2
|
3.68%
|
1,635,000
|
$124.13
|
$202,952,550
|
-3.82% (-65,000)
|
-0.16%
|
|
2021 Q1
|
3.93%
|
1,700,000
|
$118.13
|
$200,821,000
|
-1.73% (-30,000)
|
-0.07%
|
|
2020 Q3
|
4.10%
|
$103.92
|
+3.90% (+65,000)
|
|||
|
2020 Q2
|
3.65%
|
$91.70
|
+1.52% (+25,000)
|
|||
|
2020 Q1
|
4.07%
|
$90.18
|
-5.10% (-88,200)
|
|||
|
2019 Q3
|
4.28%
|
$108.62
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.